Core Viewpoint - The article discusses the strategic market operations of Haixi New Drug (02637) over the past two months, highlighting a well-planned effort to increase market capitalization and liquidity in preparation for inclusion in the Hong Kong Stock Connect program [1][3]. Group 1: Market Operation Phases - The market operation can be divided into four distinct phases aimed at enhancing and stabilizing market capitalization to meet the Hong Kong Stock Connect inclusion criteria [3]. Phase 1: Accumulation - From October 20 to October 30, the stock price rose from 97.50, increasing by 18.63% over eight trading days, with a significant trading volume of 379.17 million and a turnover rate of 4.82% [4][5]. - The bullish trading volume accounted for 87.5%, indicating strong buying power and establishing a solid foundation for future operations [4]. Phase 2: Technical Adjustment - From October 31 to November 5, the stock experienced a technical adjustment with a price decline of 5.79% and a drastic drop in trading volume to 47.87 million, reflecting a controlled "volume reduction" strategy to clear short-term floating positions [5][6]. Phase 3: Breakthrough - From November 6 to November 12, the stock surged from 112.50 to 147.00, marking a 26.49% increase with a low turnover rate of 0.79%, indicating a high level of control by the main operators [7][8]. Phase 4: Consolidation - From November 13 to December 9, the stock price stabilized around 130.54, showing strong support with more bullish days than bearish ones, preparing for further market consensus and potential value expansion [9][10]. Group 2: Market Capitalization Strategy - Haixi New Drug has submitted an application for "full circulation" of shares, which will allow major shareholders to trade their shares in the secondary market after a 12-month lock-up period, enhancing the motivation for active market capitalization management [12]. - The company aims to exceed the core requirement of a daily average market capitalization of 93 billion HKD to qualify for the Hong Kong Stock Connect, achieving a market cap of 97.7 billion HKD as of December 10 [12][13]. - The strategy is designed to secure a "market capitalization safety cushion" by significantly increasing the market cap early in the assessment period, thus reducing the risk of falling below the required threshold [12][13].

Core Viewpoint - The article discusses the strategic market operations of Haixi New Drug (02637) over the past two months, highlighting a well-planned effort to increase market capitalization and liquidity in preparation for inclusion in the Hong Kong Stock Connect program [1][11]. Group 1: Market Operation Phases - The market operation can be divided into four distinct phases aimed at enhancing and stabilizing market capitalization to meet the Hong Kong Stock Connect inclusion criteria [3][11]. Phase 1: Accumulation - From October 20 to October 30, the stock price rose from 97.50, increasing by 18.63% over eight trading days, with a significant trading volume of 379.17 million shares and a turnover rate of 4.82% [3][4]. - The buying pressure was dominant, with 87.5% of the trading volume being positive, indicating strong accumulation by the main players [3][4]. Phase 2: Technical Adjustment - From October 31 to November 5, the stock experienced a 5.79% pullback with a drastic reduction in trading volume to 47.87 million shares and a turnover rate of only 0.61% [5][6]. - This phase was characterized by a "volume contraction" strategy to clear short-term floating positions and raise the average market holding cost [5]. Phase 3: Breakthrough - From November 6 to November 12, the stock surged from 112.50 to 147.00, marking a 26.49% increase with a low turnover rate of 0.79% and 100% of the trading volume being positive [7][8]. - This indicates a high level of control by the main players, allowing for a rapid price increase with minimal capital outlay [7]. Phase 4: Consolidation - From November 13 to December 9, the stock underwent a period of consolidation around a new price level, maintaining an average price of 130.54, with more positive trading days than negative [9][10]. - This consolidation phase is crucial for building market consensus and preparing for further market capitalization expansion [9]. Group 2: Market Capitalization Strategy - Haixi New Drug has submitted an application for "full circulation" of shares, which will allow major shareholders to sell their shares in the secondary market after a 12-month lock-up period, enhancing the motivation for active market capitalization management [12]. - The company aims to exceed the minimum daily market capitalization requirement of 9.3 billion HKD to qualify for the Hong Kong Stock Connect program, with a current average market capitalization of 9.77 billion HKD as of December 10 [12][13]. - The strategy is designed to secure a "market capitalization safety cushion" by significantly increasing market value at the beginning of the assessment period, thus reducing the risk of falling below the required threshold [12][13].

Group 1: Business Outlook - The company aims to leverage its product mix advantages to penetrate various niche markets, including data centers, communications, oil and gas fields, and high-end manufacturing [2][3] - In the data center sector, the company plans to capitalize on its generator products' superior performance metrics, brand influence, market layout, and service network to expand its market share and impact [2] Group 2: Future Development of Changbo Company - Changbo Company is currently facing operational losses due to fluctuations in public vessel order demand and its wholly-owned subsidiary, Bo Xing Company, not yet realizing performance release [2][3] - The company recognizes Changbo's significant market potential and competitive advantages, including abundant business resources, well-established infrastructure, favorable geographic location, and product differentiation [3] - The strategy involves leveraging Changbo's competitive strengths through upstream and downstream industry chain collaboration to promote performance growth and achieve synergistic benefits [3] Group 3: Dividend and Shareholder Return Plans - The company places high importance on shareholder returns and actively responds to policy calls, planning to implement cash dividends twice a year based on comprehensive considerations of operational performance, financial status, market demands, and future development plans [3] - Future strategies will focus on "seeking progress while maintaining stability," emphasizing high-quality development and continuous profit improvement, while effectively utilizing various market value management tools to create greater value for investors [3]

证券日报网讯 12月10日，昊帆生物在互动平台回答投资者提问时表示，公司始终坚持以稳健经营、持 续创新和规范治理为基础，致力于为股东创造长期价值。在信息披露合规的前提下，公司积极通过多种 渠道加强与资本市场的沟通交流。公司将在市值管理方面持续优化。 （文章来源：证券日报） ...

北京北辰实业（601588）股份(00588)张超3%，截至发稿，涨2.67%，报0.77港元，成交额1299.05万港 元。 朱岩指出，公司控股股东北辰集团自2024年7月10日至2025年7月7日实施了增持公司股份的计划，提振 了资本市场对公司未来发展的信心及长期投资价值的认可。此外，北辰集团已开展新一轮增持计划，拟 于2025年10月14日起12个月内，通过上海证券交易所系统以集中竞价方式增持公司A股股份，累计增持 金额不低于人民币4500万元，不超过人民币9000万元，增持比例不超过公司总股本的2%。 消息面上，近日，北辰实业股份有限公司召开2025年第三季度业绩说明会，会上投资者提出"回购"相关 话题时，董事会秘书兼总会计师朱岩回应称，公司高度重视市值管理工作，并制定了《北辰实业市值管 理办法》及《北辰实业估值提升计划》，将常态化、系统化开展市值管理工作，推动市值与公司内在价 值相匹配。 ...

朱岩指出，公司控股股东北辰集团自2024年7月10日至2025年7月7日实施了增持公司股份的计划，提振 了资本市场对公司未来发展的信心及长期投资价值的认可。此外，北辰集团已开展新一轮增持计划，拟 于2025年10月14日起12个月内，通过上海证券交易所系统以集中竞价方式增持公司A股股份，累计增持 金额不低于人民币4500万元，不超过人民币9000万元，增持比例不超过公司总股本的2%。 智通财经APP获悉，北京北辰实业股份(00588)张超3%，截至发稿，涨2.67%，报0.77港元，成交额 1299.05万港元。 消息面上，近日，北辰实业股份有限公司召开2025年第三季度业绩说明会，会上投资者提出"回购"相关 话题时，董事会秘书兼总会计师朱岩回应称，公司高度重视市值管理工作，并制定了《 北辰实业市值 管理办法》及《北辰实业估值提升计划》，将常态化、系统化开展市值管理工作，推动市值与公司内在 价值相匹配。 ...

Core Viewpoint - The Hong Kong stock market's high dividend sector typically experiences a seasonal "bull market" from December to mid-January, driven by historical patterns known as the "calendar effect" [1] Historical Data Insights - The Hong Kong Stock Connect High Dividend Total Return Index shows a high absolute return probability of 90.9% from December to mid-January, with a median increase of 3.4% and an average increase of 4.6% since 2014 [2] - The probability of achieving excess returns compared to the A-share market (CSI 300) is 81.8%, with an average outperformance of approximately 2.1 percentage points [3] - The same probability of 81.8% applies when comparing to the A-share dividend index (CSI Dividend), with an average excess return of about 3.2 percentage points [4] - When compared to the Hong Kong market benchmark (Hang Seng Index), the probability of excess returns is also 81.8%, with an average excess return of approximately 1.6 percentage points [5] Exceptions and Insights - The only year with absolute return losses was from December 2015 to mid-January 2016, attributed to the A-share "leverage bull" collapse and liquidity crisis affecting the Hong Kong market. However, high dividend assets still outperformed the A-share market and the Hang Seng Index during this period [6] - Years where excess returns lagged behind the A-share market occurred mainly during the "fast bull" phases of 2014-2015 and 2020-2021, when growth stocks surged [6] - Excess returns lagging behind the Hang Seng Index were primarily due to significant movements in major stocks like Tencent, rather than a widespread trend [6] Investment Strategy - Investing in high dividend assets in the Hong Kong market at year-end is historically a high-probability strategy with both absolute and relative return potential, influenced by institutional portfolio adjustments and the dividend distribution system [7] - Among the high dividend stocks, those from state-owned enterprises (SOEs) may offer lower valuations and more stable dividend guarantees, as SOEs have implemented market value management and accountability systems [8] - The CSI Hong Kong Stock Connect SOE Dividend Index has a price-to-book ratio (PB) of 0.63, lower than the 0.66 for the broader high dividend index, providing a thicker "safety cushion" [8] - As of December 9, the one-year dividend yield for this index is 6.71%, surpassing the 4.84% yield of 10-year government bonds, with the largest investment vehicle tracking this index being the Hong Kong SOE Dividend ETF [8]

Core Viewpoint - Linglong Tire emphasizes the importance of market value management and has implemented various strategies to enhance production efficiency, reduce costs, and improve product quality, aiming to strengthen profitability and market competitiveness in a complex environment [1] Group 1: Company Strategies - The company has focused on optimizing production processes, improving equipment efficiency, and implementing lean production management to enhance capacity utilization [1] - Linglong Tire is committed to digital transformation and innovation in research and marketing systems to further bolster its operational capabilities [1] - The company aims to mitigate international trade risks through a balanced global presence and business layout [1] Group 2: Financial Management - Linglong Tire has maintained a high dividend payout ratio of over 30% annually, reflecting its commitment to shareholder returns [1] - The company has undertaken initiatives such as share buybacks and increasing dividend frequency to stabilize market confidence [1] - Future plans include enhancing corporate governance, transparent information disclosure, and effective communication with investors to support long-term value growth [1]

证券日报网讯12月9日，鹏鼎控股（002938）在互动平台回答投资者提问时表示，股价受市场形势变 化、投资者风险偏好等因素影响，公司在经营层面运营状况正常。公司始终以打造良好的公司基本面作 为市值管理的根本，努力强化经营管理能力，不断提升公司内在价值，也敬请投资者注意投资风险。 ...

证券日报网讯12月9日，玲珑轮胎（601966）在互动平台回答投资者提问时表示，公司现阶段正在对标 优秀同行，全力提升研发、制造、营销、采购、服务等生产经营各环节的效率和效益，以促进盈利能力 的不断增强，同时通过全球产地和业务的均衡布局提升市场竞争力和抵御风险能力，并结合公司治理、 信息披露、投资者关系管理、ESG体系建设，持续稳定的分红等多重举措不断完善市值管理工作，努力 用长期持续的良好业绩回馈广大投资者。 ...